Loading...
MRK logo

Merck KGaAXTRA:MRK Stok Raporu

Piyasa Değeri €63.3b
Hisse Fiyatı
n/a
1Y32.4%
7D9.5%
1D-0.9%
Portföy Değeri
​
Görünüm

Merck KGaA

XTRA:MRK Stok Raporu

Piyasa değeri: €63.3b

Merck KGaA (MRK) Hisse Özeti

Merck KGaA, Almanya'da bir bilim ve teknoloji şirketi olarak faaliyet göstermektedir. Daha fazla detay

Ödüller

Adil değer tahminimizden 52.5% daha düşük bir oranda işlem görüyor

Kazançların yılda 8.91% oranında artması öngörülüyor

Risk Analizi

Risk kontrollerimizden MRK için herhangi bir risk tespit edilmedi.

MRK Community Fair Values

Create Narrative

See what 74 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives

Merck KGaA Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Merck KGaA
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı€145.65
52 Haftanın En Yüksek Seviyesi€147.70
52 Haftanın En Düşük Seviyesi€100.70
Beta0.81
1 Aylık Değişim11.31%
3 Aylık Değişim35.36%
1 Yıllık Değişim32.41%
3 Yıllık Değişim-2.02%
5 Yıllık Değişim-10.84%
Halka arzdan bu yana değişim839.13%

Son Haberler & Güncellemeler

Anlatı Güncellemesi • Jun 22

MRK: Life Science Tools Recovery Will Support Future Upside Potential

Analysts recently adjusted their views on Merck KGaA after Street price targets diverged, including a cut to €129 at one firm that now sees a more balanced risk and reward, and a raise to €160 at another firm citing early signs of recovery in life science tools. Analyst Commentary Recent commentary on Merck KGaA reflects a split view, with some bullish analysts highlighting early signs of improvement in key segments such as life science tools, while others see the current share price as broadly aligned with the company's exposure to structural growth drivers.
Anlatı Güncellemesi • Jun 06

MRK: Life Science Tools Recovery And Lower AI Risk Will Support Upside

Merck KGaA's updated analyst price target now centers around €160, up from €135, with analysts pointing to cautious optimism around life science tools, a more balanced risk and return profile, and sector wide reassessments of recovery potential and valuation. Analyst Commentary Recent research points to a mixed but generally firming stance on Merck KGaA.

Recent updates

Anlatı Güncellemesi • Jun 22

MRK: Life Science Tools Recovery Will Support Future Upside Potential

Analysts recently adjusted their views on Merck KGaA after Street price targets diverged, including a cut to €129 at one firm that now sees a more balanced risk and reward, and a raise to €160 at another firm citing early signs of recovery in life science tools. Analyst Commentary Recent commentary on Merck KGaA reflects a split view, with some bullish analysts highlighting early signs of improvement in key segments such as life science tools, while others see the current share price as broadly aligned with the company's exposure to structural growth drivers.
Anlatı Güncellemesi • Jun 06

MRK: Life Science Tools Recovery And Lower AI Risk Will Support Upside

Merck KGaA's updated analyst price target now centers around €160, up from €135, with analysts pointing to cautious optimism around life science tools, a more balanced risk and return profile, and sector wide reassessments of recovery potential and valuation. Analyst Commentary Recent research points to a mixed but generally firming stance on Merck KGaA.
Anlatı Güncellemesi • May 23

MRK: Healthcare Resilience And Raised 2026 Guidance Will Support Future Upside

Narrative Update on Merck KGaA Analysts now see fair value for Merck KGaA at about €143, up from roughly €141, reflecting recent price target revisions and views that healthcare could appeal to investors given the current macro backdrop, geopolitical risks, and perceived lower exposure to AI disruption risks. Analyst Commentary Recent research snapshots show a mixed stance on Merck KGaA, with some analysts trimming price targets and others taking a more neutral starting point.
Anlatı Güncellemesi • Apr 30

MRK: Healthcare Resilience And Sustainable Solvents Will Support Future Upside

The updated analyst price target for Merck KGaA moves modestly lower to about €141 from around €143, reflecting recent target cuts from firms citing a cautious macro backdrop and sector specific views, while still recognizing potential interest in healthcare as investors weigh geopolitical risk and AI related disruption. Analyst Commentary Recent research on Merck KGaA has focused on recalibrating expectations, with multiple firms trimming price targets and one major house initiating coverage with a neutral stance.
Anlatı Güncellemesi • Apr 15

MRK: Reset Expectations And 2026 Guidance Will Shape Future Return Balance

Analysts have trimmed the fair value estimate for Merck KGaA from €127.00 to €112.00, reflecting recent reductions in Street price targets and a more cautious stance on profitability, despite slightly higher modeled revenue growth. Analyst Commentary Recent Street research on Merck KGaA has tilted more cautious, with several bearish analysts cutting price targets and reassessing the risk and reward balance.
Anlatı Güncellemesi • Apr 01

MRK: Lower AI Disruption Risk And Margin Resilience Will Support Future Upside

Analysts have trimmed the fair value estimate for Merck KGaA from €187.48 to €172.13 as recent price target cuts and more cautious ratings have offset slightly higher revenue growth and profit margin assumptions, along with a lower future P/E multiple. Analyst Commentary Recent research shows a mixed set of opinions on Merck KGaA, but with some clear pockets of optimism that help frame the trimmed fair value estimate.
Anlatı Güncellemesi • Mar 18

MRK: Healthcare Resilience And Limited AI Disruption Will Drive Future Upside

Analysts have trimmed the Merck KGaA fair value estimate from €143.88 to €143.20. This reflects recent cuts to Street price targets in light of a tougher macro backdrop, geopolitical risk and more tempered expectations around sector exposure to AI related disruption.
Anlatı Güncellemesi • Mar 04

MRK: Margin Resilience And New TGCT Therapy Will Shape Future Upside

Analysts have lifted their price target on Merck KGaA to €130 from €125, citing slightly stronger assumptions for revenue growth, profit margins and future P/E, even as recent rating changes across the sector keep overall views balanced. Analyst Commentary Recent research on Merck KGaA reflects a split view, with some firms turning more cautious while others highlight steady execution and valuation support.
Anlatı Güncellemesi • Feb 18

MRK: Margin Gains And HPC Buildout Will Shape Future Upside Potential

Analysts have raised their price target on Merck KGaA to €130 from €125, citing updated expectations for slightly lower revenue growth, a modestly higher discount rate, and a small uplift in projected profit margin and future P/E assumptions. Analyst Commentary Recent research on Merck KGaA presents a mixed picture, but there is a clear cluster of constructive views around valuation, profitability, and execution.
Anlatı Güncellemesi • Feb 03

MRK: Mixed Rating Shifts Will Shape Perceived Balance Of Future Return Potential

Narrative Update: Merck KGaA Analysts have inched their average price target for Merck KGaA up by €5 to €130. This reflects updated views on earnings potential and risk after recent research, including a downgrade at Deutsche Bank and a price target adjustment at Barclays.
Anlatı Güncellemesi • Jan 20

MRK: Refined Earnings Outlook Points To Balanced Future Return Potential

Analysts have lifted their fair value estimate for Merck KGaA to €127 from €105, citing updated assumptions for revenue growth, profit margins and future P/E multiples that are broadly in line with recent Street target moves, such as the new €130 level from Barclays. Analyst Commentary The recent move to a €130 price target from €125 sits broadly in line with the updated fair value estimate of €127, which suggests that expectations are being fine tuned rather than reset.
Anlatı Güncellemesi • Jan 06

MRK: Future Earnings Power And HPC Expansion May Support Upside

Narrative Update on Merck KGaA Analysts have trimmed their price target for Merck KGaA by €20 to €130, citing updated assumptions that reflect a fair value of €184.63, a discount rate of 4.93%, revenue growth of 5.19%, a profit margin of 16.10%, and a future P/E of 23.44x. Analyst Commentary Recent Street research signals that analysts are reassessing Merck KGaA's valuation framework, with the latest work reflecting a price target of €130 compared with a prior level of €150.
Anlatı Güncellemesi • Dec 21

MRK: Future Price Cut Signals Slowing Earnings Momentum Ahead

Analysts have trimmed their price target on Merck KGaA to EUR 130 from EUR 150, reflecting slightly lower long term revenue growth and margin expectations, even as they acknowledge the company's ability to sustain a higher future price to earnings multiple. Analyst Commentary Bearish analysts point to a more challenging backdrop for Merck KGaA, with reduced expectations for long term top line expansion and profitability prompting a reassessment of fair value.
Anlatı Güncellemesi • Dec 07

MRK: Margin Strength And AI Deal Will Drive Future Upside

Analysts have trimmed their price target on Merck KGaA, cutting it by EUR 20 to EUR 130 as they factor in slightly softer long term revenue growth assumptions, even though profit margin expectations have improved modestly. Analyst Commentary Analysts are recalibrating their views on Merck KGaA, with the reduced price target reflecting a more measured stance on the company’s medium to long term prospects while acknowledging an improved profitability outlook.
Anlatı Güncellemesi • Nov 23

MRK: New Leadership Change And AI Partnership Will Drive Shares Higher

Analysts have modestly lowered their price target for Merck KGaA from €150 to €130. They cite a combination of slightly reduced profit margin forecasts and an increased discount rate, even though there is a small uptick in expected revenue growth.
Anlatı Güncellemesi • Nov 03

MRK: Future CEO Appointment Will Support Recovery and Restore Confidence

The analyst price target for Merck KGaA has been reduced from EUR 150 to EUR 130, as analysts cite softer growth expectations and recent earnings disappointments. Analyst Commentary Recent street research reflects a cautious tone among analysts regarding Merck KGaA, with a series of price target reductions and rating adjustments.
Anlatı Güncellemesi • Oct 20

Global Biotechnology And Digital Automation Will Drive Future Healthcare

Analysts have trimmed their fair value estimate for Merck KGaA from €147.53 to €145.94. This change reflects a series of recent price target reductions and persistent concerns regarding growth prospects and limited near-term catalysts.
Anlatı Güncellemesi • Sep 04

Global Biotechnology And Digital Automation Will Drive Future Healthcare

Merck KGaA's consensus price target remains unchanged at €147.53 as analysts adopt a more neutral stance following disappointing Q2 results, lowered guidance, and reduced near-term growth visibility. Analyst Commentary Disappointing Q2 report and weaker-than-expected operational performance.
Analiz Makalesi • Jul 24

We Think Merck KGaA (ETR:MRK) Can Stay On Top Of Its Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analiz Makalesi • Jul 03

Merck KGaA's (ETR:MRK) Share Price Not Quite Adding Up

With a median price-to-earnings (or "P/E") ratio of close to 19x in Germany, you could be forgiven for feeling...
User avatar
Yeni Anlatı • Nov 24

AI-Driven Semiconductor Surge Powers Healthcare And Electronics To New Heights

Strong growth in semiconductor solutions and life sciences boosts Merck's Electronics and Process Solutions sectors, positively impacting future revenue and earnings.

Hissedar Getirileri

MRKDE PharmaceuticalsDE Pazar
7D9.5%14.9%-1.7%
1Y32.4%44.5%-0.6%

Getiri vs. Endüstri: MRK geçen yıl % 44.5 oranında getiri sağlayan German Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: MRK geçen yıl % -0.6 oranında getiri sağlayan German Piyasasını aştı.

Fiyat Oynaklığı

Is MRK's price volatile compared to industry and market?
MRK volatility
MRK Average Weekly Movement4.6%
Pharmaceuticals Industry Average Movement5.8%
Market Average Movement5.7%
10% most volatile stocks in DE Market13.4%
10% least volatile stocks in DE Market2.8%

İstikrarlı Hisse Senedi Fiyatı: MRK son 3 ayda German piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: MRK 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
166859,077Kai Beckmannwww.emdgroup.com

Merck KGaA, Almanya'da bir bilim ve teknoloji şirketi olarak faaliyet göstermektedir. Yaşam Bilimleri, Sağlık Hizmetleri ve Elektronik segmentleri aracılığıyla faaliyet göstermektedir. Şirketin Yaşam Bilimleri segmenti, akademik laboratuvarlar, biyoteknoloji ve ilaç üreticilerinin yanı sıra endüstriyel sektör için araçlar, kimyasallar ve ekipmanlar sunmaktadır.

Merck KGaA Temel Bilgiler Özeti

Merck KGaA'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
MRK temel i̇stati̇sti̇kler
Piyasa değeri€63.33b
Kazançlar(TTM)€2.53b
Gelir(TTM)€20.96b
25.0x
F/K Oranı
3.0x
P/S Oranı

MRK aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
MRK gelir tablosu (TTM)
Gelir€20.96b
Gelir Maliyeti€8.61b
Brüt Kâr€12.35b
Diğer Giderler€9.82b
Kazançlar€2.53b

Son Raporlanan Kazançlar

Mar 31, 2026

Sonraki Kazanç Tarihi

Aug 06, 2026

Hisse başına kazanç (EPS)5.82
Brüt Marj58.93%
Net Kâr Marjı12.08%
Borç/Özkaynak Oranı40.4%

MRK uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

1.5%
Mevcut Temettü Verimi
38%
Ödeme Oranı

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/06/29 06:09
Gün Sonu Hisse Fiyatı2026/06/26 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Merck KGaA 42 Bu analistlerden 15, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Odile RundquistBaader Helvea Equity Research
Gerhard SchwarzBaader Helvea Equity Research
Charles PitmanBarclays